US Genomics Market Size Projected to Reach USD 72.75 Billion by 2034 with a CAGR of 18.62%

IMARC Group has recently released a new research study titled "United States Genomics Market Report by Component (Products, Services), Technology (Sequencing, Microarray, Polymerase Chain Reaction, Nucleic Acid Extraction and Purification, Others), Application (Functional Genomics, Epigenomics, Biomarkers Discovery, Pathway Analysis, Others), End User (Research Centers, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others), and Region 2026-2034," offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

US Genomics Market Size, Growth, and Forecast (2026-2034)

The US genomics market size was valued at USD 15.64 Billion in 2025 and is projected to reach USD 72.75 Billion by 2034, growing at a CAGR of 18.62% during 2026-2034. The market is experiencing robust growth driven by increasing adoption of precision medicine approaches across healthcare systems and expanding applications in oncology diagnostics, rare disease identification, and pharmacogenomics.

Major research institutions and healthcare networks are integrating genomic testing into clinical workflows, while pharmaceutical and biotechnology companies leverage genomic insights for drug discovery and development programs. Government initiatives, including the NIH All of Us Research Program, continue to advance population-scale genomic research, accelerating the translation of genomic discoveries into clinical practice and driving sustained demand for genomic products and services across the US genomics market share.

The United States genomics market occupies a leadership position globally, supported by world-class research infrastructure, substantial federal funding, and pioneering healthcare institutions advancing genomic medicine. The ecosystem benefits from strong public-private partnerships that accelerate the translation of genomic discoveries into clinical applications, including expanding contributions to the US clinical genomics market as hospitals and reference laboratories integrate genomic testing into standard care protocols.

The integration of artificial intelligence and machine learning with genomic data analysis is transforming biomarker discovery and drug development pipelines, while declining sequencing costs continue to expand accessibility across both clinical and research settings nationwide.

Explore Growth Opportunities in the US Genomics Market - Grab Your Sample Report for Evaluation:https://www.imarcgroup.com/united-states-genomics-market/requestsample

Key Trends Driving the US Genomics Market

• Expansion of multiomics integration in research and clinical applications: The convergence of genomics with proteomics, metabolomics, and transcriptomics is creating comprehensive biological insights that enhance disease understanding and treatment development, with leading technology providers expanding portfolios spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, and epigenetics.
• Rising adoption of liquid biopsy technologies for non-invasive cancer detection: Liquid biopsy technologies utilizing circulating tumor DNA and cell-free DNA analysis are gaining significant traction for cancer screening, monitoring treatment response, and detecting minimal residual disease, with clinical laboratories and oncology centers continuing to expand liquid biopsy offerings to support personalized treatment strategies.
• Artificial intelligence integration transforming genomic data analysis: Machine learning algorithms and AI platforms are revolutionizing the interpretation of complex genomic datasets, enabling faster identification of clinically significant variants. In January 2025, the Broad Institute of MIT and Harvard partnered with Manifold to bring a unique life science research and development platform incorporating AI capabilities to investigators worldwide.
• Expanding applications of precision medicine across healthcare systems: The integration of genomic testing into clinical practice continues expanding as the US clinical genomics market grows, with oncology applications leading adoption through tumor profiling that guides targeted therapy selection, while pharmacogenomics testing helps optimize drug dosing and reduce adverse reactions.
• Substantial government funding supporting genomic research infrastructure: Federal investment through National Institutes of Health programs provides foundational support for genomic research advancement, with the National Human Genome Research Institute funding genome center expansions, including an April 2025 award to the HudsonAlpha Institute for long-read whole genome sequencing capabilities.
• Technological innovation reducing sequencing costs and expanding accessibility: Continuous advancement in sequencing platforms, chemistry, and analytical software drives dramatic reductions in per-genome costs while improving data quality and throughput, expanding accessibility of genomic testing across clinical laboratories and research institutions.

US Genomics Market Report Segmentation:

The US Genomics Market report provides a detailed segmentation analysis to help businesses identify key growth segments and evolving industry trends. The market is categorized based on component, technology, application, end user, and region, offering comprehensive insights into demand patterns across the United States.

Component Insights:

• Products: Products dominate the market with a share of 68% in 2025, encompassing sequencing instruments, consumables, reagents, microarray platforms, and associated software essential for genomic research and clinical applications. In October 2024, Illumina unveiled the MiSeq i100 Series of benchtop sequencing systems, incorporating technology and chemistry from the NovaSeq X Series across eighteen end-to-end workflows covering applications from microbiology to oncology.
• Services: Services, including core genomics services, NGS-based services, biomarker translation services, and computational services, support research institutions and healthcare organizations that require specialized expertise beyond in-house capabilities.

Technology Insights:

• Sequencing: Sequencing leads the market with a share of 48% in 2025, attributed to continuous advancements in next-generation sequencing platforms offering enhanced accuracy, scalability, and cost efficiency. In June 2024, Illumina completed integration of its XLEAP-SBS chemistry into all reagents for its NextSeq 1000 and NextSeq 2000 instruments, enabling faster run times and higher output at lower cost per kit.
• Microarray: Microarray technology continues to support genomic research applications requiring high-throughput analysis of gene expression and genetic variation across large sample sets.
• Polymerase Chain Reaction: Polymerase chain reaction technology remains a foundational tool across genomic research and diagnostic applications, valued for its speed, sensitivity, and cost-effectiveness.
• Nucleic Acid Extraction and Purification: Nucleic acid extraction and purification technologies support the critical upstream sample preparation processes required across virtually all genomic testing and research workflows.
• Others: Includes additional genomic technologies supporting specialized research and clinical applications across the sector.

Application Insights:

• Functional Genomics: Functional genomics applications support research into gene function and regulation, contributing to broader understanding of disease mechanisms and therapeutic targets.
• Epigenomics: Epigenomics applications examine heritable changes in gene expression, supporting research into disease susceptibility and treatment response beyond genetic sequence alone.
• Biomarkers Discovery: Biomarkers discovery represents the largest application segment with a market share of 26% in 2025, owing to its critical role in identifying therapeutic targets for oncology and supporting precision medicine treatment strategies. In October 2024, leading cancer research organizations launched patient enrollment for myeloMATCH, a National Cancer Institute-overseen portfolio of precision medicine clinical trials focused on myelodysplastic syndrome and acute myeloid leukemia.
• Pathway Analysis: Pathway analysis applications help researchers understand the biological pathways underlying disease processes, supporting drug discovery and development programs.
• Others: Includes additional genomic applications supporting diverse research and clinical objectives across the healthcare and life sciences sectors.

End User Insights:

• Research Centers: Research centers hold the largest share of 36% in 2025, reflecting substantial investments by academic institutions and government-funded research organizations in genomic studies. The Broad Institute of MIT and Harvard, which houses one of the largest genome sequencing centers worldwide, engages scientists from partner institutions and industry in collaborative research programs.
• Hospitals and Clinics: Hospitals and clinics represent a growing end user segment as the US clinical genomics market expands, with healthcare providers increasingly integrating genomic testing into standard diagnostic and treatment protocols across oncology, rare disease, and pharmacogenomics applications.
• Pharmaceutical and Biotechnology Companies: Pharmaceutical and biotechnology companies leverage genomic insights for drug discovery and development programs, using biomarker data to accelerate clinical trial design and support precision medicine treatment approaches.
• Others: Includes additional end users such as consumer genomics providers and specialized diagnostic laboratories supporting the broader genomics ecosystem.

Regional Insights:

• Northeast: The Northeast represents one of the dominant genomics hubs, anchored by world-class research institutions including the Broad Institute of MIT and Harvard and Memorial Sloan Kettering Cancer Center, concentrated in the Boston-Cambridge and New York metropolitan areas, benefiting from substantial NIH funding and deep venture capital networks.
• Midwest: The Midwest demonstrates growing prominence in genomics through established research universities including the University of Chicago and Northwestern University, combined with expanding manufacturing capabilities and clinical laboratory networks.
• South: The South exhibits accelerating genomics activity centered around Texas medical centers and North Carolina's Research Triangle Park, with Houston's Texas Medical Center, the world's largest medical complex, receiving substantial NIH funding for healthcare and life sciences initiatives between 2020 and 2024.
• West: The West maintains leadership in genomics innovation driven by San Diego's concentration of sequencing technology companies and the San Francisco Bay Area biotechnology ecosystem, housing headquarters of leading genomics companies and benefiting from robust venture capital funding.

Competitive Landscape:

The United States genomics market exhibits a consolidated competitive structure in sequencing platforms, with established players maintaining substantial market positions, while demonstrating fragmentation across consumables, services, and specialized applications. Market leaders pursue strategies combining organic innovation with strategic acquisitions to expand product portfolios, increasingly differentiating through integrated sample-to-insight workflows, cloud-based analytics platforms, and comprehensive customer support services.

US Genomics Market Recent News and Developments:

• Foundation Medicine launches new germline tests: In February 2025, Foundation Medicine announced plans to launch two new germline tests, FoundationOne Germline and FoundationOne Germline More, in the United States to identify genetic variants associated with hereditary cancers, helping healthcare providers understand underlying risk for patients and families.
• Thermo Fisher Scientific partners with National Cancer Institute: In July 2024, Thermo Fisher Scientific partnered with the National Cancer Institute on the myeloMATCH precision medicine umbrella trial, utilizing next-generation sequencing technology to match acute myeloid leukemia and myelodysplastic syndrome patients with appropriate clinical trials across North America.

Challenges Impacting the US Genomics Market

High-profile data breaches and concerns regarding genetic data security have impacted consumer participation in direct-to-consumer testing programs, reducing sample availability for population-scale research initiatives and requiring substantial cybersecurity investment.

Variable insurance coverage and reimbursement policies for genomic testing create market access barriers, particularly for novel applications lacking established clinical utility evidence, limiting adoption of testing outside established oncology and rare disease applications.

The rapid expansion of genomic data generation outpaces availability of qualified professionals capable of interpreting complex datasets, with research institutions and healthcare organizations competing for limited talent in bioinformatics and clinical genomics.

Investment Opportunities in the US Genomics Market

The US genomics market offers compelling investment opportunities supported by its strong 18.62% CAGR through 2034. AI-powered genomic data analysis platforms represent a high-growth opportunity as machine learning continues to transform biomarker discovery and variant interpretation.

The US clinical genomics market presents an expanding investment category, as hospitals and reference laboratories increasingly integrate genomic testing into standard oncology, rare disease, and pharmacogenomics protocols.

Liquid biopsy and non-invasive testing technologies offer attractive returns as clinical laboratories and oncology centers continue expanding offerings to support personalized treatment strategies and early cancer detection.

Outlook of the US Genomics Market (2026-2034)

The United States genomics market demonstrates strong growth potential supported by expanding clinical applications in oncology, rare disease diagnostics, and pharmacogenomics, alongside increasing integration of genomic testing into standard healthcare protocols. The market generated revenue of USD 15.64 Billion in 2025 and is projected to reach USD 72.75 Billion by 2034, growing at a CAGR of 18.62% from 2026-2034.

As long-read sequencing platforms, single-cell analysis solutions, spatial transcriptomics capabilities, and AI-powered interpretation tools continue to enhance the utility and accessibility of genomic technologies, the US genomics market is expected to sustain strong growth momentum, enabling healthcare providers to deliver more precise diagnostic and therapeutic solutions nationwide.

Frequently Asked Questions (FAQs): US Genomics Market

1. How big is the US genomics market?

The US genomics market size was valued at USD 15.64 Billion in 2025.

2. What is the projected growth rate of the US genomics market?

The US genomics market is expected to grow at a CAGR of 18.62% from 2026-2034 to reach USD 72.75 Billion by 2034.

3. Which component held the largest US genomics market share?

Products dominated the market with a 68% share in 2025, driven by extensive demand for sequencing instruments, consumables, and reagents essential for genomic research and clinical diagnostics applications.

4. What are the key factors driving market growth?

Key factors include expanding precision medicine applications across healthcare systems, substantial government funding through NIH programs supporting research infrastructure, and continuous technological innovation reducing sequencing costs while improving accessibility.

5. What is the US clinical genomics market?

The US clinical genomics market refers to the segment of the broader genomics industry focused on integrating genomic testing into hospital and clinical settings, supporting applications such as oncology diagnostics, rare disease identification, and pharmacogenomics.

6. Which technology leads the US genomics market?

Sequencing leads the market with a 48% share in 2025, attributed to continuous advancements in next-generation sequencing platforms offering enhanced accuracy, scalability, and cost efficiency.

7. Which application segment is largest in the market?

Biomarkers discovery holds the largest application share at 26% in 2025, owing to its critical role in identifying therapeutic targets for oncology and supporting precision medicine treatment strategies.

8. Which region leads the US genomics market?

The Northeast represents one of the dominant genomics hubs, anchored by world-class research institutions, while the West, South, and Midwest also represent significant regional markets.

9. What are the major challenges facing the US genomics market?

Major challenges include data privacy and security concerns affecting consumer confidence, variable reimbursement policies creating market access barriers, and skilled workforce shortages in bioinformatics and genomic analysis.

Author IMARC Group

IMARC Group is a leading global management consulting firm providing in-depth market research, strategic advisory services, and feasibility studies. The firm empowers organizations worldwide with actionable insights and data-driven strategies to support sustainable growth and informed decision-making.

Contact Us

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302

Professional helping brands decode markets and grow smarter. I write about strategy, trends, and data-backed decision-making.